 |
|
|
| |
Switching to a Fixed-Dose Combination of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in Virologically Suppressed, Treatment-Experienced People with HIV (PWH) ≥ 65 Years Old
|
| |
| |
Itl Aging & HIV Workshop, Oct 26-27
Tulika Singh, MD,1 Roque Anthony Velasco, NP,1 Ian McNicholl, PharmD,2 Cathy Chien, MD2 1 DAP Health, Palm Springs, CA, 2Gilead Sciences, Foster City, CA
|
| |
|
|
|
|
|
